BCByounggook Cho

Byounggook Cho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Byounggook Cho has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Aberrant neural stem cell quiescence is the gateway to autism development linked to Arid1b

    by Byounggook Cho, Hongwon Kim, Saemin An, Yerim Hwang, Daeyeol Kwon, Jeonghyun Park, Christopher J. Lengner, Jongpil Kim

    Autism spectrum disorder is a neurodevelopmental disorder with social communication deficits, repetitive behaviors, and restricted interests. While previous studies have demonstrated a close link between aberrant neurogenesis and the development of autism, a fundamental question remains unresolved: Does the anomalous neurogenesis observed in autism serve as a causative factor, and if so, could restoring aberrant neurogenesis alleviate autistic behaviors? In this study, we demonstrate that the manifestation of autistic behaviors can be caused by the aberrant activity of quiescent neural stem cells (qNSCs), resulting from the conditional deletion of Arid1b in adult brain NSCs. Particularly, increased H3K27me3 levels in qNSCs due to conditional Arid1b deficiency precipitated autism-related phenotypes, but rescuing this through H3K27me3 inhibition effectively reversed autistic-like phenotypes. Importantly, we also found quiescent like NSCs in humans carrying the ARID1B mutation, as well as in NSCs of sporadic autism patients. These results highlight the significant role of aberrant qNSCs associated with adult neurogenesis for autism development in adult brain, offering a novel avenue for potentially controlling qNSC activity as a therapeutic strategy for autism.


  • Dormant state of quiescent neural stem cells links Shank3 mutation to autism development

    by Hongwon Kim, Byounggook Cho, Hanseul Park, Junyeop Kim, Siyoung Kim, Jaein Shin, Christopher J. Lengner, Kyoung-Jae Won, Jongpil Kim

    Autism spectrum disorders (ASDs) are common neurodevelopmental disorders characterized by deficits in social interactions and communication, restricted interests, and repetitive behaviors. Despite extensive study, the molecular targets that control ASD development remain largely unclear. Here, we report that the dormancy of quiescent neural stem cells (qNSCs) is a therapeutic target for controlling the development of ASD phenotypes driven by Shank3 deficiency. Using single-cell RNA sequencing (scRNA-seq) and transposase accessible chromatin profiling (ATAC-seq), we find that abnormal epigenetic features including H3K4me3 accumulation due to up-regulation of Kmt2a levels lead to increased dormancy of qNSCs in the absence of Shank3. This result in decreased active neurogenesis in the Shank3 deficient mouse brain. Remarkably, pharmacological and molecular inhibition of qNSC dormancy restored adult neurogenesis and ameliorated the social deficits observed in Shank3-deficient mice. Moreover, we confirmed restored human qNSC activity rescues abnormal neurogenesis and autism-like phenotypes in SHANK3-targeted human NSCs. Taken together, our results offer a novel strategy to control qNSC activity as a potential therapeutic target for the development of autism.